Compare PAGSEG Inc (PAGS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7 and net income margin of 10.45%, supported by recent earnings beats. A dividend of $0.28 is scheduled for September 2026. Analyst consensus is bullish with a $10.70 price target, though RSI levels indicate potential overbought conditions near-term.

The outlook for PAGS is positive given its undervalued metrics and profitability, but risks include macroeconomic pressures in Brazil and elevated credit losses. Institutional interest remains strong, with recent buys from Bank of America. The stock presents a value opportunity with dividend income, though investors should monitor earnings consistency and interest rate impacts.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.